Colorectal Cancer Recurrent
16
7
7
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (16)
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
Microbiome and Colorectal Cancer Recurrence
Stage II/III Colorectal Cancer Recurrence
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA
Early-Onset Colorectal Cancer Recurrence
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
A Study of Famitinib in Patients With Advanced Colorectal Cancer